Clinical Trials on CMML

Total 158 results

University of Florence

Recruiting

Pilot Study of CC 486 (Oral Azacitidine) Plus BSC as Maintenance After sc Azacitidine in Elderly HR-IPSS-R MDS Patients (FLO_CC-486-)

MDS | CMML

Italy
Fujifilm Pharmaceuticals U.S.A., Inc.

Completed

Study of FF-10501-01 in Patients With Relapsed or Refractory Hematological Malignancies

AML | MDS | CMML

United States
Groupe Francophone des Myelodysplasies
GlaxoSmithKline; Novartis

Completed

A Study of Eltrombopag in Patients With CMML and Thrombocytopenia

Thrombocytopenia | CMML

France
Inhibikase Therapeutics, Inc.

Recruiting

A Dose Calibration Study Comparing IkT-001Pro to Imatinib Mesylate 400mg

CML

United States
Pfizer

Completed

Palatability (Taste) of Oral Formulations of Bosutinib

CML

Belgium
Rabin Medical Center
Rambam Health Care Campus; Hadassah Medical Organization; HaEmek Medical Center... and other collaborators

Unknown

Treatment Modification Based on Early Assessment of CML Patients

CML

Israel
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Completed

The Study of the Efficacy and the Safety of Flumatinib vs Imatinib as First Line Treatment in Patients With CML

CML, CML-CP,MMR,TKI

China
DKMS gemeinnützige GmbH

Recruiting

GvHD Prophylaxis in Unrelated Donor HCT: Randomized Trial Comparing PTCY Versus ATG (GRAPPA)

AML | MDS | Peripheral Blood Stem Cell Transplantation | Graft Vs Host Disease | CMML | MDS/MPN

Germany
Spirita Oncology, LLC

Terminated

A Study of E6201 for the Treatment of Advanced Hematologic Malignancies With FLT3 and/or Ras Mutations

AML | MDS | CMML

United States
Novartis Pharmaceuticals

Active, not recruiting

Study to Allow Access to Imatinib for Patients Who Are on Imatinib Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator

GIST and CML

China, Turkey, Singapore, France, Switzerland, Thailand, United States, Romania, Hong Kong, Finland, United Kingdom
Air Force Military Medical University, China
The Second Hospital of Hebei Medical University; Qilu Hospital of Shandong... and other collaborators

Recruiting

Azacitidine and Homoharringtonine in JMML

JMML

China
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Terminated

Axitinib and Bosutinib in Treating Patients With Chronic, Accelerated, or Blastic Phase Chronic Myeloid Leukemia

Accelerated Phase Chronic Myelogenous Leukemia (CML) | Blast Phase Chronic Myelogenous Leukemia (CML) | Chronic Phase Phase Chronic Myelogenous Leukemia (CML) | Philadelphia Chromosome Positive (Ph+) Phase Chronic Myelogenous Leukemia (CML)

United States
Novartis Pharmaceuticals

Completed

An Exploratory Study of High-dose Glivec in Patients With CML-CP Using Molecular Endpoints (CML)

Imatinib | CML

Korea, Republic of
European Society for Blood and Marrow Transplantation
Novartis

Completed

Non Interventional Study on Iron Toxicity After First Allo-transplant in MDS/CMML

MDS | CMML

Germany, Belgium, Czechia
Novartis Pharmaceuticals

Completed

A Study That Switched Patients From Imatinib to Nilotinib and Then Was Followed by Treatment Cessation (ENESTgoal)

CML

United States
Immune-Onc Therapeutics
California Institute for Regenerative Medicine (CIRM)

Recruiting

IO-202 as Monotherapy and IO-202 Plus Azacitidine ± Venetoclax in Patients in AML and CMML

CMML | AML With Monocytic Differentiation

United States
Humanigen, Inc.

Completed

Study of Lenzilumab in Previously Treated Patients With Chronic Myelomonocytic Leukemia (CMML)

Chronic Myelomonocytic Leukemia (CMML)

United States
National Taiwan University Hospital

Completed

Distress, Medication Adherence and Care Needs in Patients With CML and GIST Receiving Oral Targeted Therapy

GIST | CML

Taiwan
UNC Lineberger Comprehensive Cancer Center

Completed

Precision Dosing of Tyrosine Kinase Inhibitors in CML Patients

Chronic Myeloid Leukemia | Chronic Myeloid Leukemia, Chronic Phase | CML, Chronic Phase | CML - Philadelphia Chromosome | CML (Chronic Myelogenous Leukemia

United States
Sheffield Children's NHS Foundation Trust

Withdrawn

Gene Expression Profiles in CML Non-responders

Gene Expression Profiles in CML Non-responders

United Kingdom
University of Utah
Genentech, Inc.

Recruiting

Cobimetinib in Newly Diagnosed or HMA-treated CMML Patients With RAS Pathway Mutations (CONCERTO)

Chronic Myelomonocytic Leukemia (CMML)

United States
St. Jude Children's Research Hospital

Completed

Haploidentical Stem Cell Transplantation for Patients With Hematologic Malignancies

Myelodysplastic Syndrome (MDS) | Leukemia, Acute Lymphocytic (ALL) | Leukemia, Myeloid, Acute(AML) | Leukemia, Myeloid, Chronic(CML) | Hemoglobinuria, Paroxysmal Nocturnal (PNH) | Lymphoma, Non-Hodgkin (NHL) | Juvenile Myelomonocytic Leukemia(JMML)

United States
Il-Yang Pharm. Co., Ltd.

Recruiting

A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs

Chronic Myeloid Leukemia, Chronic Phase | CML, Chronic Phase | CML, Refractory | CML - Philadelphia Chromosome

Turkey, Korea, Republic of, Russian Federation, Ukraine
iOMEDICO AG

Completed

Non-interventional Study With Azacitidin (Vidaza®) (Piaza)

AML | MDS | CMMOL

Germany
Astex Pharmaceuticals, Inc.

Completed

SGI-110 in Patients With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)

AML | MDS | CMML

United States, Canada
Samsung Medical Center

Unknown

Feasibility and Efficacy Study of Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation (HCT) With Fludarabine, Busulfan, and Total Body Irradiation (TBI)

Lymphoma | AML | MDS | CML | ALL

Korea, Republic of
Abramson Cancer Center of the University of Pennsylvania

Completed

Sirolimus in Combination With MEC in High Risk Myeloid Leukemias (UPCC 02407)

Leukemia | AML | CML | Myeloid Leukemias

United States
Sensei Biotherapeutics, Inc.

Withdrawn

SNS-301 Monotherapy in High Risk MDS and CMML

Myelodysplastic Syndromes | Chronic Myelomonocytic Leukemia (CMML)
Cytheris, Inc.

Completed

Safety Study of IL-7 in Recipients of a Hemopoietic Stem Cell Transplant Peripheral Blood Stem Cell Transplant

AML | MDS | CML

United States
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Recruiting

A Study of HS-10382 in Patients With Chronic Myeloid Leukemia.

CML, Chronic Phase | CML, Accelerated Phase

China
Novartis Pharmaceuticals

Completed

Tasigna in Glivec-resistant or Intolerant Patients in CML

CML | Nilotinib | Imatinib Resistant | Imatinib Intolerant

Korea, Republic of
Synta Pharmaceuticals Corp.

Completed

STA-9090 for Treatment of AML, CML, MDS and Myeloproliferative Disorders

Myeloproliferative Disorders | AML | MDS | CML

United States
Beth Israel Deaconess Medical Center
Amgen

Completed

Nonmyeloablative Allo SCT for the Treatment of Hematologic Disorders (MINI HEME)

AML | MDS | CLL | ALL | CML Chronic Phase, Accelerated Phase, or Blast Crisis | RELAPSED NON-HODGKIN'S OR HODGKIN'S LYMPHOMA | APLASTIC ANEMIA | MULTIPLE MYELOMA | MYELOPROLIFERATIVE DISORDER (P Vera, CMML, ET)
Newave Pharmaceutical Inc

Recruiting

Dose-Escalation Study of Oral Administration of LP-108 as Monotherapy and in Combination With Azacitidine in Patients With Relapsed or Refractory MDS, CMML, or AML

Refractory Acute Lymphoblastic Leukemia | Relapse | CMML | Relapsed Adult AML | AML/MDS | Relapse Leukemia

United States, Spain
Treadwell Therapeutics, Inc

Recruiting

A Study of CFI-400945 With or Without Azacitidine in Patients With AML, MDS or CMML (TWT-202)

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Chronic Myelomonocytic Leukemia | AML | MDS | CMML

Hong Kong, United States, Canada
Van Andel Research Institute

Completed

Ascorbic Acid Levels in MDS, AML, and CMML Patients

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Chronic Myelomonocytic Leukemia | AML | MDS | CMML

United States
H. Lee Moffitt Cancer Center and Research Institute
Pfizer

Completed

Phase II Hedgehog Inhibitor for Myelodysplastic Syndrome (MDS)

Chronic Myelomonocytic Leukemia (CMML) | Myelodysplastic Syndrome (MDS)

United States
Novartis Pharmaceuticals

Completed

Nilotinib in Newly Diagnosed Adult Philadelphia Chromosome & /or BCR-ABL Positive Chronic Myeloid Leukaemia in Chronic Phase ('MACS1252)

CML in Chronic Phase

Germany, Italy, Spain, Belgium, Croatia, Hungary, Netherlands, Austria, France, Greece, Sweden, Switzerland, Bulgaria, Romania, Slovenia, United Kingdom, Lithuania, Slovakia, Denmark, Finland, Norway, Poland, Czech Republic, Portugal, E... and more
BioLite, Inc.

Not yet recruiting

A Study of BLEX 404 Oral Liquid in Patients With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-Risk Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML)

Myelodysplastic Syndrome (MDS)
Peking University People's Hospital

Recruiting

Assessment of Measurable Residual Disease in Allo-HSCT Using Digital Polymerase Chain Reaction

Acute Leukemia | MDS | CML | MDS/MPN

China
TetraLogic Pharmaceuticals

Terminated

Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL

Chronic Myelomonocytic Leukemia (CMML) | Myelodysplastic Syndrome (MDS)

United States, Spain, Australia, Germany
Erimos Pharmaceuticals

Terminated

Phase 1 Study of Terameprocol (EM-1421) in Patients With Leukemia

Chronic Lymphocytic Leukemia (CLL) | Acute Myeloid Leukemia (AML) | Chronic Myelomonocytic Leukemia (CMML) | Myelodysplastic Syndrome (MDS) | Acute Lymphocytic Leukemia (ALL) | Leukemias | Adult T Cell Leukemia (ATL) | Chronic Myeloid Leukemia (CML-BP)

United States
Novartis Pharmaceuticals

Terminated

Study of Nilotinib in Ph+ CML-CP Patients With Low Imatinib Trough Plasma Concentrations (MACS1148)

CML | Philadelphia Chromosome Positive (Ph+) | Chronic Myelogenous Leukemia Chronic Phase(CML-CP) Patients With Low Imatinib Trough Levels

United States
Nerviano Medical Sciences

Recruiting

Study of NMS-03592088 in Patients With Relapsed or Refractory AML or CMML

Acute Myeloid Leukemia (AML) | Chronic Myelomonocytic Leukemia (CMML)

Italy, Spain, France
Ascentage Pharma Group Inc.

Recruiting

A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Chronic Myelomonocytic Leukemia | AML | MDS | CMML | High-risk Myelodysplastic Syndrome

United States
Nanexa AB
Uppsala University

Completed

Pharmacokinetics, Tolerability and Safety of NEX-18a

Myelodysplastic Syndromes (MDS) | Acute Myeloid Leukemia (AML) | Chronic Myelomonocytic Leukemia (CMML)

Sweden
Sidney Kimmel Comprehensive Cancer Center at Johns...
Io Therapeutics

Terminated

Study of IRX5183 in Relapsed and Refractory Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome

Acute Myeloid Leukemia (AML) | Chronic Myelomonocytic Leukemia (CMML) | Myelodysplastic Syndrome (MDS)

United States
Merck Sharp & Dohme LLC

Completed

Study of Sotatercept for the Treatment of Anemia in low-or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) or Non-proliferative Chronic Myelomonocytic Leukemia (CMML)

Myelodysplastic Syndromes | Anemia | Chronic Myelomonocytic Leukemia | Myelodysplastic Syndromes (MDS) | Chronic Myelomonocytic Leukemia (CMML) | Low to Intermediate-1 MDS

United States, France
medac GmbH
Syneos Health; Celerion

Completed

Treosulfan-based Conditioning in Paediatric Patients With Haematological Malignancies

Myelodysplastic Syndromes (MDS) | Acute Lymphoblastic Leukaemias (ALL) | Acute Myeloid Leukaemias (AML) | Juvenile Myelomonocytic Leukaemias (JMML)

Germany, United Kingdom, Italy, Austria, Czechia, Poland
University of Alabama at Birmingham

Not yet recruiting

CD34 Selection Using the Automated CliniMACS Prodigy

Myelodysplastic Syndromes | Primary Myelofibrosis | AML | Lymphoid Malignancies | CML | ALL

United States

Clinical Trials on CMML

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Peru

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations